Latest market price
1.03
-0.11-9.65%
OverviewShort InterestFilings
VRXAVeraxa Biotech Holding AG·NASDAQ
1.03-9.65%
TA
Loading chart...
Signal & projected range
Insider open-market buyHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
QURE-7.49%$22.97RARE+1.24%$16.30NUVB-3.57%$4.59TRAX-0.07%$45.05NTLA-6.50%$11.66ABSI-12.94%$9.69URGN+5.01%$34.36MAZE-3.53%$30.37
Snapshot
Index—P/E—EPS (ttm)—Insider Own4.12%Shs Outstand141.41MPerf Week5.10%
Market Cap145.65MForward P/E—EPS next Y—Insider Trans1.63%Shs Float12.61MPerf Month-8.85%
Enterprise Value—PEG—EPS next Q—Short Float0.85%Perf Quarter-42.78%
Income—P/S—EPS this Y—Short Ratio0.37Perf Half Y—
Sales—P/B—EPS next Y—ROA—Short Interest107.38KPerf YTD-92.64%
Book/sh—P/C—EPS next 5Y—ROE—52W High27.39 -96.24%Perf Year—
Cash/sh—P/FCF—EPS past 3/5Y—ROIC—52W Low0.95 8.42%Perf 3Y—
Dividend Est.—EV/EBITDA—Sales past 3/5Y—Gross Margin—Volatility12.00% 11.40%Perf 5Y—
Dividend TTM—EV/Sales—EPS Y/Y TTM—Oper. Margin—ATR (14)0.13Perf 10Y—
Dividend Ex-Date—Quick Ratio—Sales Y/Y TTM—Profit Margin—RSI (14)41.44Recom—
Dividend Gr. 3/5Y—Current Ratio—EPS Q/Q—SMA20-4.85%Beta2.93Target Price—
Payout—Debt/Eq—Sales Q/Q—SMA50-21.39%Rel Volume1.10Prev Close1.14
Employees8LT Debt/Eq—Earnings—SMA200-62.28%Avg Volume260.69KPrice1.03
IPO DateJun 09, 2026Option/ShortNo / YesEPS/Sales Surpr.—Net Debt/EBITDA—Volume286,810Change-9.65%
Latest News· Times ET
Oct-21-26
Oct-21-2603:00PM
VERAXA Biotech (VRXA) Expands Human-Relevant Testing Strategy to Advance Antibody-Based Cancer PipelineYahoo
Oct-13-26
Oct-13-2603:30PM
VERAXA Biotech (VRXA) Presents First In Vivo Proof-of-Concept Data for BiTAC-ADC Platform at World ADC CongressYahoo
07:00AM
VERAXA Biotech Presents in vivo Proof-of-Concept Data for BiTAC®-ADC Technology at World ADC Congressglobenewswire.com
Oct-07-26
Oct-07-2603:00PM
VERAXA Biotech (VRXA) Advances FDA-Aligned Methods to Reduce Animal TestingYahoo
09:09AM
Micro-Cap Stock Veraxa Biotech Is Down 96% This Year. Can Next-Gen Drug Testing Save It?barrons.com
07:00AM
VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategyglobenewswire.com
Sep-24-26
Sep-24-2603:38PM
VERAXA Biotech (VRXA) Advances Oncology Pipeline as Xlife Sciences Reports First-Half ProgressYahoo
Sep-22-26
Sep-22-2602:30PM
VERAXA Biotech (VRXA) Builds Oncology Pipeline Around BiTAC Platform, Public-Market Story Enters Next PhaseYahoo
Sep-16-26
Sep-16-2603:00PM
VERAXA Biotech (VRXA) Building a New Approach to Precision Cancer TherapyYahoo
Sep-09-26
Sep-09-2611:46AM
VERAXA Biotech Designates Raju Willener as CFOYahoo
Sep-04-26
Sep-04-2612:30PM
These stocks are moving in today's sessionChartMill
07:00AM
VERAXA Biotech Appoints Raju Willener as Chief Financial Officerglobenewswire.com
Aug-24-26
Aug-24-2603:10AM
VERAXA Biotech Announces Initial Results From Strategic Research Collaboration To Develop Next-Generation Antibody Oligonucleotide Conjugates For Autoimmune And Chronic Immune Diseases; In Early In Vitro Studies, An AOC Candidate Demonstrated Greater PotencyBenzinga
Jul-31-26
Jul-31-2601:17PM
Veraxa Biotech Files Prospectus Related To The Resale Of Up To 25M Ordinary Shares By The Selling ShareholderBenzinga
Jul-29-26
Jul-29-2607:00AM
VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidatesglobenewswire.com
Company

Veraxa Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation. The company was founded in 2021 and is based in Heidelberg, Germany.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Insider Trading Volume
$28.36$20.62$12.88$5.15$-2.59● Close Price0.00K20.66K41.33K61.99K82.65KUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Gruninger MarcDirectorOct 28 '26Buy1.009,1339,13310,000Oct 29
Gruninger MarcDirectorOct 27 '26Buy0.98867850867Oct 29
Ziegler Christoph SamuelDirectorOct 20 '26Buy1.0930,00032,70037,932Oct 21
Baumann Oliver RolfDirectorAug 27 '26Buy1.5050,00075,0005,773,618Aug 31
Antz Christoph RudigerChief Executive OfficerAug 27 '26Buy1.535,0007,6505,000Aug 31
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.